BHC Bausch Health Corp Forward P/S Multiple

Corporate company logo of Bausch Health Companies (BHC)

Bausch Health Companies (BHC) is implementing eco-friendly packaging and relying on a stable global environment due to the industry's humanitarian status. The forward P/S ratio captures shifts in market revenue expectations, where 0.30 shows the current value of the metric. The holding company's prospects are based on the success of Xifaxan, a strong dermatology pipeline, and the potential spin-off of Bausch + Lomb to reduce debt.

Bausch Health Companies Inc. - BHC Forward P/S Multiple (period 07/04/2022 - 11/13/2026)

Analytical breakdowns for Bausch Health Companies

- current price and projected stock value:
Stock Price Bausch Health|BHC - Analyst Target Range
- market capitalization data:
Market Capitalization Bausch Health Corp|BHC - Total Company Value
- issuer book value statistics:
Book Value per Share Bausch Health|BHC - Book Capitalization|Market Cap to Net Assets Ratio bauschhealth.com|BHC - Company Total Assets
- business debt structure and liquidity details:
Debt to Equity Bausch Health Companies|BHC - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Bausch Health Companies|BHC - Company Total Debt|Debts to Book Capitalization Bausch Health Corp|BHC - Company Long-Term Loans and Borrowings|Company Current Liabilities Bausch Health|Quick Ratio bauschhealth.com
- financial results and valuation multiples details:
BHC - Final Profit|Projected Future Earnings Bausch Health Companies|BHC - Market Cap to Earnings|Forward P/E Multiple Valeant Pharmaceuticals|BHC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bausch Health Corp|BHC - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Bausch Health|BHC - Earnings per share for the last four quarters|Quarterly EPS earnings growth bauschhealth.com|BHC - Earnings per share increase in current year|Expected earnings per share growth for next year Bausch Health Companies
- total revenue and sales volume data:
BHC - Company Sales Revenue|Projected Sales Volume Bausch Health|BHC - Market Cap to Revenue|Price-to-Projected Revenue Ratio Bausch Health Corp
Analysis of all company metrics:Bausch Health BHC
Original product of Bausch Health Corp

Production automation of lenses and pharmaceuticals at Bausch Health Companies (BHC) optimizes the operational base, yet the reliance on the intellectual labor of scientists during formula development impacts revenue forecasts. By analyzing the business's forward P/S, an investor assesses current capitalization relative to expected sales: a stable ratio confirms its status as a defensive asset, while a sharp decline signals a loss of market confidence in the company's stability.

Key competitors

Forward P/S Multiple LLY (Eli Lilly)|Projected Price to Revenue AbbVie Inc|AstraZeneca AB - Forward P/S Multiple|NVS: Price-to-Projected Revenue Ratio|MRK: Forward P/S Multiple|novonordisk.com (NVO) - Forward P/S Multiple|Forward Price-to-Revenue Multiple AMGN|Forward P/S Multiple Pfizer Inc|Price-to-Projected Revenue Ratio Sanofi Aventis (SNY)|Market Cap to Expected Sales Ratio Bristol-Myers Squibb Co.|Forward P/S Multiple GSK (GlaxoSmithKline)|TAK - Forward Price-to-Revenue Multiple|Teva - Forward P/S Multiple|Forward Price to Sales RDY (Dr. Reddy's Laboratories Limited)|VTRS (Viatris Corp) - Forward Price-to-Revenue Multiple|Roivant Corp - Forward Price to Sales|ZLAB (Zai Lab Limited) - Forward P/S Multiple|COSM: Forward Price to Sales